Success Story: NAILG Helped a Chinese Expert Earn NIW Approval via Premium Processing

Client’s Testimonial:

“WeGreened’s streamlined process and responsive team made my NIW application smooth and stress-free. Their clear guidance saved me time and helped me present my achievements effectively. Highly recommended.”

On March 31^st, 2025, we received another EB-2 NIW (National Interest Waiver) approval for an Expert in the Field of Medical Research (Approval Notice).

General Field: Medical Research

Position at the Time of Case Filing: Unemployed

Country of Origin: China

Approval Notice Date: March 31^st, 2025

Processing Time: 1 month, 27 days (Premium Processing Requested)

Case Summary:

The North America Immigration Law Group (NAILG) is delighted to announce the successful approval of an I-140 petition under the EB-2 category with a National Interest Waiver (NIW) for a highly skilled expert in medical research. The petition was filed with premium processing and was approved within two months, recognizing the client’s groundbreaking contributions to the development of personalized treatment strategies for cancer and other complex diseases.

Our client, who holds an M.D., is a specialist in medical research with a focus on utilizing statistical models and artificial intelligence to interpret genomic and clinical datasets. Her work supports the development of customized therapies that aim to maximize treatment efficacy and minimize adverse effects in patients suffering from serious illnesses, particularly cancer. She is currently employed in a research-oriented position within the biotechnology sector, where she continues to pursue this nationally important work.

To establish that the client is well-positioned to advance her proposed endeavor and that her work holds substantial merit and national importance, our firm presented a thorough body of evidence, highlighting:

Robust Publication Record: The client has authored 13 peer-reviewed journal articles, including 7 as first author, and 1 first-authored abstract, underscoring her leadership in publishing impactful research in high-impact journals.
Meaningful Research Impact: Her published work has been cited 126 times, with several papers ranking among the top 10–20% of most cited in the field of Clinical Medicine for their publication year. This strong citation record reflects significant scholarly influence and validation from the broader scientific community.
Peer Recognition and Implementation: The client’s research has been directly cited by other specialists working in cancer, demonstrating her role in shaping clinical practice and advocating individualized treatment
Expert Peer Reviewer: Her professional standing is further illustrated by her peer review activity for recognized scientific journals, reinforcing her authority in the field and the trusted judgment of other researchers’ work.
Original Contributions of Major Significance: The petition emphasized her innovative work on the clinical use of statistical algorithms and evidence-based treatment that contribute directly to enhanced patient survival and recovery strategies.

Through a precisely constructed petition, NAILG successfully demonstrated that the client satisfies all prongs of the Dhanasar framework for a national interest waiver. The USCIS recognized that her continued research will yield direct benefits to public health and technological advancement in the United States.

This approval underscores NAILG’s commitment to supporting top-tier researchers in emerging biomedical fields whose work is shaping the future of medicine and contributing to the well-being of society.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.